HUT50494A - Process for producing peptide analogs in large numbers, as well as new type peptide analogs - Google Patents
Process for producing peptide analogs in large numbers, as well as new type peptide analogs Download PDFInfo
- Publication number
- HUT50494A HUT50494A HU886575A HU657588A HUT50494A HU T50494 A HUT50494 A HU T50494A HU 886575 A HU886575 A HU 886575A HU 657588 A HU657588 A HU 657588A HU T50494 A HUT50494 A HU T50494A
- Authority
- HU
- Hungary
- Prior art keywords
- analogs
- threonine
- dna sequences
- dna
- large number
- Prior art date
Links
- 108020004414 DNA Proteins 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims abstract description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- BKKWZCSSYWYNDS-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O BKKWZCSSYWYNDS-JEDNCBNOSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 7
- 102000053602 DNA Human genes 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000009452 underexpressoin Effects 0.000 abstract 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 241000557626 Corvus corax Species 0.000 description 2
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Es wird ein Verfahren zur Erzeugung einer groszen Anzahl von Analoga eines gewaehlten Peptids beschrieben. Das Verfahren umfaszt die folgenden Schritte: Synthetisierung von zwei unterschiedlichen Gemischen von gleichlangen Oligonucleotiden, die an einigen bestimmten Positionen unterschiedliche Basen und am 3-Ende einige identische Basen besitzen, Mischen der beiden Gemische zur Bildung eines Gemischs von partiell doppelstraengigen, gleichlangen DNA-Sequenzen, die danach enzymatisch in vollstaendig doppelstraengige DNA-Sequenzen umgewandelt werden, Schneiden des zuletzt genannten Gemischs mit zwei verschiedenen Enzymen zur Erzeugung von DNA-Sequenzen, die an einen in aehnlicher Weise geschnittenen Vektor ligiert werden koennen, Inserieren der DNA-Sequenzen in den Vektor durch Ligation, um ein Gemisch von Vektoren zu erzeugen, die dann in einer an sich bekannten Art und Weise in einen Wirt transformiert werden, Vermehrung des Wirts zur Bildung von Kolonien, die nacheinander analysiert werden, um die DNA-Sequenzen festzustellen, die fuer ein einzelnes Protein codieren, unter Expressionsbedingungen separate Vermehrung der groszen Anzahl von Wirten zur Erzeugung einer groszen Anzahl von Analoga des gewaehlten Peptids. Auszerdem werden neue Analoga von VIP und ein Plasmid, das ein Gen enthaelt, das fuer eines der neuen Analoga von VIP codiert, offenbart.{Verfahren; Herstellung; Peptid; Oligonucleotide; Basen; 3-Ende; DNA-Sequenzen; Enzyme; Vektor}
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8705139A SE8705139D0 (sv) | 1987-12-23 | 1987-12-23 | Forfarande for framstellning av ett stort antal peptidanaloger och nya peptidanaloger |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUT50494A true HUT50494A (en) | 1990-02-28 |
Family
ID=20370695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU886575A HUT50494A (en) | 1987-12-23 | 1988-12-22 | Process for producing peptide analogs in large numbers, as well as new type peptide analogs |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0391957A1 (de) |
| JP (1) | JPH03502880A (de) |
| DD (1) | DD294500A5 (de) |
| HU (1) | HUT50494A (de) |
| SE (1) | SE8705139D0 (de) |
| WO (1) | WO1989005857A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141924A (en) * | 1989-06-30 | 1992-08-25 | Hoffmann-La Roche, Inc. | Synthetic vasoactive intestinal peptide analogs |
| JPH06507415A (ja) * | 1991-04-25 | 1994-08-25 | コーマン，ルイス・ワイ | 胃腸管の一時的な麻痺誘発のためのバソアクティブインテスティナルペプチド（ｖｉｐ）の使用 |
| WO1994004563A1 (fr) * | 1992-08-14 | 1994-03-03 | Shino-Test Corporation | PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS |
| JPH06306100A (ja) * | 1993-04-26 | 1994-11-01 | Sanwa Kagaku Kenkyusho Co Ltd | Ｖｉｐアナログ調製用融合蛋白、ｖｉｐアナログの製法並びにそのための遺伝子組換えプラスミド及び形質転換微生物 |
| CN1124283C (zh) * | 1995-06-09 | 2003-10-15 | 伊藤火腿株式会社 | 一种肽、一种支气管扩张剂,和一种血流促进剂 |
| GB2313376A (en) * | 1996-05-22 | 1997-11-26 | Diapharm Limited | Polypeptide immunologically cross-reactive with NTM peptide and with vasoactive intestinal peptide (VIP) |
| AU2002220720B2 (en) | 2000-11-28 | 2006-09-14 | Mondobiotech Ag | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
| CA2488358A1 (en) | 2002-06-10 | 2003-12-18 | Mondobiotech Laboratories Anstalt | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis |
| ES2368565T3 (es) * | 2002-11-27 | 2011-11-18 | Ils Inc. | Péptidos y composiciones medicinales que contienen los mismos. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985002198A1 (en) * | 1983-11-01 | 1985-05-23 | Amgen | Microbial expression of type i transforming growth factor, polypeptide analogs thereof and hybrid egf/tgf polypeptides |
| US4605641A (en) * | 1984-10-09 | 1986-08-12 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
| GB8427651D0 (en) * | 1984-11-01 | 1984-12-05 | Beecham Group Plc | Compounds |
| EP0194006B1 (de) * | 1985-02-01 | 1992-04-29 | Imperial Chemical Industries Plc | Analoge Interferon-Polypeptide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| GB8525852D0 (en) * | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
-
1987
- 1987-12-23 SE SE8705139A patent/SE8705139D0/xx unknown
-
1988
- 1988-12-21 WO PCT/SE1988/000696 patent/WO1989005857A1/en not_active Ceased
- 1988-12-21 JP JP1500471A patent/JPH03502880A/ja active Pending
- 1988-12-21 EP EP89900676A patent/EP0391957A1/de not_active Withdrawn
- 1988-12-22 HU HU886575A patent/HUT50494A/hu unknown
- 1988-12-22 DD DD88323713A patent/DD294500A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DD294500A5 (de) | 1991-10-02 |
| SE8705139D0 (sv) | 1987-12-23 |
| EP0391957A1 (de) | 1990-10-17 |
| WO1989005857A1 (en) | 1989-06-29 |
| JPH03502880A (ja) | 1991-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strydom et al. | Amino acid sequence of human tumor derived angiogenin | |
| EP0293357B1 (de) | Expression von menschlichem Proapolipoprotein A-1 | |
| Watanabe et al. | A peptide that stimulates phosphorylation of the plant insulin‐binding protein: isolation, primary structure and cDNA cloning | |
| US4549986A (en) | Human CGRP | |
| Sauer et al. | Primary structure of the phage P22 repressor and its gene c2 | |
| HUT50494A (en) | Process for producing peptide analogs in large numbers, as well as new type peptide analogs | |
| JP3531947B2 (ja) | ペプチドの製造方法 | |
| JP2537029B2 (ja) | 成長ホルモン放出因子の製造方法 | |
| Wurtz et al. | A new protein expressed in bone marrow cells and osteoblasts with implication in osteoblast recruitment | |
| Hartl et al. | The N terminus of laminin A chain is homologous to the B chains | |
| CA1339464C (en) | ¬leu13| motilin, dnas coding for same and methods for producing same | |
| HU197939B (en) | Process for producing deoxyribonucleic acid, or its precursor, determining human growth hormone releasing factor | |
| FR2716205A1 (fr) | Récepteur galanine, acides nucléiques, cellules transformées et utilisations. | |
| US4736023A (en) | DNA encoding human CGRP | |
| JPH05236962A (ja) | 新規酵素及びそれをコードするｄｎａ | |
| WO1994019469A1 (fr) | Proteine de fusion multi-vip et procede de preparation de vip recombinant | |
| EP0336155A1 (de) | Menschliche rekombinante Herzmyosin | |
| WO1995001431A1 (fr) | Famille de peptides appeles xenoxines | |
| US5420113A (en) | [Leu13]motilin, DNAs coding for same and methods for producing same | |
| US5695952A (en) | Method for producing Leu13 !motilin | |
| DE3220333C2 (de) | ||
| EP0706567B1 (de) | Peptide-familie, genannt xenoxine | |
| JPS61111688A (ja) | ヒトエラスタ−ゼ１の生物工学的製造 | |
| KR0132003B1 (ko) | 스트렙토마이세스 써모니트리피컨스 아미노펩티다제를 이용한 천연형 재조합 단백질의 제조방법 | |
| JPH0322986A (ja) | 新規なｄｎａ単離物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFC9 | Refusal of application |